For instance, entinostat, a class I histone deacetylase (HDAC) inhibitor, reduced the expression of RAD51 and FANCD2, which, in turn, sensitized melanoma cells to TMZ and allowed for synthetic lethal targeting of PARP with olaparib [118]. The gene discussed is HDAC9; the disease is melanoma.